ReviewCancers2016
Photodynamic Therapy for Non-Melanoma Skin Cancers.
Review in Cancers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- Xeroderma Pigmentosum: A Genetic Condition Skin Cancer Correlated-A Systematic Review.BioMed research international · 2022Pooled it
- Photodynamic Therapy for Keratinocytic Precancerous Lesions and Non-Melanoma Skin Cancer: A Narrative Review.International journal of molecular sciences · 2026Review
- 5-ALA in Oncology: Current Clinical Applications, Biological Limitations, and Emerging Translational Strategies.Biomedicines · 2026Review
- Safety and Efficacy of Aminolevulinic Acid Hydrochloride Topical Gel, 10%, with Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma In Situ.The Journal of clinical and aesthetic dermatology · 2026Article
- Ce6 derivative photodynamic therapy triggers PANoptosis and enhances antitumor immunity with LAG3 blockade in cutaneous squamous cell carcinoma.Cell reports. Medicine · 2025Article
- Expert consensus-based recommendations on the use of photodynamic therapy in actinic keratosis patients.JAAD international · 2025Article
- Recent advancements and perspectives of photoresponsive inorganic nanomaterials for cancer phototherapy and diagnosis.RSC advances · 2025Review
- Phototherapy in cancer treatment: strategies and challenges.Signal transduction and targeted therapy · 2025Review
- The m-TORC1 inhibitor Sirolimus increases the effectiveness of Photodynamic therapy in the treatment of cutaneous Squamous Cell Carcinoma, impairing NRF2 antioxidant signaling.International journal of biological sciences · 2024Article
- Effect of skin color on optical properties and the implications for medical optical technologies: a review.Journal of biomedical optics · 2024Review
- Exploiting Unique Features of Microneedles to Modulate Immunity.Advanced materials (Deerfield Beach, Fla.) · 2023Review
- Advances in Photodynamic Therapy for the Treatment of Actinic Keratosis and Nonmelanoma Skin Cancer: A Narrative Review.Dermatology and therapy · 2023Review
- Phosphorescent Metal Halide Nanoclusters for Tunable Photodynamic Therapy.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
- An insight into photodynamic therapy towards treating major dermatological conditions.Journal of drug delivery science and technology · 2022Article
- Non-melanoma skin cancers: physio-pathology and role of lipid delivery systems in new chemotherapeutic treatments.Neoplasia (New York, N.Y.) · 2022Review
- Article
- Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy.Molecular metabolism · 2022Article
- The evolution of clinical guidelines for antimicrobial photodynamic therapy of skin.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2022Review
- Novel Water-Soluble Chlorin-Based Photosensitizer for Low-Fluence Photodynamic Therapy.ACS pharmacology & translational science · 2022Article
- PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma.Oncoimmunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-melanoma skin cancer (NMSC) is traditionally treated with surgical excision. Nonsurgical methods such as cryotherapy and topical chemotherapeutics, amongst other treatments, are other options. Actinic keratosis (AKs) are considered precancerous lesions that eventually may progress to squamous cell carcinoma (SCC). Photodynamic therapy (PDT) offers an effective treatment for AKs, and is also effective for superficial basal cell carcinoma (BCC). Nodular BCC and Bowen's disease (SCC in situ) have shown acceptable response rates with PDT, although recurrence rates are higher for these two NMSC subtypes. Methylaminolevulinate (MAL) PDT is a more effective treatment option than 5-aminolevulinic acid (ALA) PDT for nodular BCC. Several studies have shown that PDT results in superior cosmetic outcomes compared to surgical treatment. PDT is overall well-tolerated, with pain being the most common side effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.